An antibody raised against a region close to the N terminal of the zinc efflux transporter ZnT-8 (SLC30A8). Zinc transporters (ZnT) regulate the passage of zinc across biological membranes out of the cytosol. ZnT-8 plays a role in insulin regulation and the development of type II diabetes.
Catalogue number crb2005635 Antibody Anti-SLC30A8 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200841e Protein ID Q8IWU4-1 Human SLC30A8 Aliases Solute carrier family 30 member 8, SLC30A8, Zinc transporter 8, ZnT-8, ZNT8 Cross-Reactivity Human Target Protein Species Human Host Species Rabbit Antibody Type Polyclonal Concentration 1mg/ml (DAB035) Target SLC30A8 Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Family Hominidae Disease Area Diabetes- Diabetes mellitus Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Dwivedi et al., (2019). Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. Nat Genet. 51(11): 1596. PMID: 31676859.
Kleiner et al., (2018). Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity PNAS USA. 115(32): E7642. PMID: 30038024
Syring et al., (2020). Potential Positive and Negative Consequences of ZnT8 Inhibition. J Endocrinol. 246(2): 189. PMID: 32485672
Zinc is a a highly toxic biological molecule and is regulated by levels and localisation to ensure cellular homeostasis. This is facilitated by two families of zinc transporters; the SLC39 family (also called ZIPs) uptake zinc while the SLC30 family (ZnT) oppose this function by zinc efflux to the extracellular matrix or intracellular organelles, including ZnT-8. ZnT-8 is highly expressed in the islets of Langerhans within pancreatic β-cells, where it transports zinc ions for crystallisation and storage of insulin. Mutation of zinc transporters are well reported to be deleterious. However, loss of function mutations to ZnT-8 (SLC30A8) provide protection against type II diabetes. ZnT-8 is also being explored as an autogen for type I diabetes and also as a marker for prediabetic patients. This makes it a strong candidate for drug discovery and thus this antibody has the potential to aid that research.